London’s Mamedica Secures £4.5M Funding Led by U.S. Venture Firm Casa Verde

Casa Verde has invested in leading U.S. cannabis companies such as Dutchie, Metrc, and Leaflink, and holds European stakes in Cansativa and Sanity Group. The new funding will enable Mamedica to scale operations by streamlining its supply chain, expanding clinical access, enhancing its digital healthcare platform, and promoting medical cannabis education.

Founded in 2022 by CEO Jon Robson, Mamedica offers specialist treatment for chronic and neurological conditions such as pain, anxiety, ADHD, and depression. Its digital platform enables remote consultations with specialist clinicians and next-day nationwide medication delivery.

Read Also - Wexler.ai Raises $5.3M To Deliver Real-Time Fact Intelligence For Litigation

Since launch, Mamedica has treated over 10,000 patients, with 7,500 actively under care, achieving roughly 10% month-on-month growth in initial consultations, 1,250% patient growth in 2023, and 154% in 2024, and aims to double patient numbers annually as the UK medical cannabis market nears £1bn by 2028.

“We’re excited to partner with Mamedica as the UK cannabis market enters a period of rapid growth” said Karan Wadhera Managing Partner at Casa Verde. “Mamedica’s digital-first, patient-centric model sets the standard for care in the UK and offers a blueprint for broader European expansion.”

“This funding marks a pivotal milestone in Mamedica’s mission to transform patient care in the UK,” said Jon Robson CEO and founder of Mamedica. “The backing of Casa Verde and our private investors validates our approach and enables us to accelerate access to high-quality, regulated treatment.”

About Mamedica

Mamedica is a UK digital healthcare platform offering cannabis-based prescription medicines for pain, neurology, psychiatry, palliative care and cancer. After secure video consultations, medications are delivered nationwide via next-day courier. The platform ensures patient safety and satisfaction through specialist clinicians, experienced pharmacists, proprietary technology, and dedicated support staff.